Table II.
Patient characteristics and comparison of the detection of peritoneal metastases under white light and fluorescence excitation.
| Peritoneal assessment | |||||||
|---|---|---|---|---|---|---|---|
| Case | Clinical diagnosis | Operation | Pathological diagnosis of specimen | TNM classificationa | WL | BL | Histological diagnosis of nodule |
| 1 | PK | UR | T4N0M0 Stage III/ | + | + | Pm | |
| T4N0M1 Stage IV | |||||||
| 2 | PK | PH | Lm | T3N0M0 Stage IIA/ | − | ||
| T3N0M1 Stage IV | |||||||
| 3 | PK | DP | CP | T2N0M0 Stage IIA/− | − | ||
| 4 | PK | PD | IDC | T3N0M0 Stage IIA/ | + | − | − |
| T3N1M0 Stage IIB | |||||||
| 5 | PK | PD | IPMC (invasive) | TN0M0 Stage IIA/ | − | ||
| T3N0M0 Stage IIA | |||||||
| 6 | PK | DP | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 7 | PK | PD | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N1M0 Stage II | |||||||
| 8 | PK | DP | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N0M0 Stage IIA | |||||||
| 9 | PK | SL | T4N1M0 Stage III/ | − | |||
| T4N1M0 Stage III | |||||||
| 10 | PK | UR | T3N1M0 Stage IIA/ | − | |||
| T4N1M0 Stage III | |||||||
| 11 | PK | SL | T3N0M0 Stage IIA/ | − | |||
| T3N0M0 Stage IIA | |||||||
| 12 | PK | PD | IDC | T3N1M0 Stage IIB/ | − | ||
| T3N0M0 Stage IIA | |||||||
| 13 | PK | DP | IDC | T4N0M0 Stage II/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 14 | PK | SL | T3N0M0 Stage IIA/ | − | |||
| T3N0M0 Stage IIA | |||||||
| 15 | PK | UR | T3N0M0 Stage IIA/ | + | + | Pm | |
| T3N0M1 Stage IV | |||||||
| 16 | PK | DP | In situ | T1N0M0 Stage IA/ | − | ||
| TisN0M0 Stage 0 | |||||||
| 17 | PK | PD | In situ | T3N0M0 Stage IIA/ | − | ||
| TisN0M0 Stage 0 | |||||||
| 18 | PK | DP | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 19 | IPMC | PD | IPMC | T1N0M0 Stage IA/ | − | ||
| T1N0M0 Stage IA | |||||||
| 20 | PK | PD | IPMC (invasive) | T2N0M0 Stage IB/ | − | ||
| T2N0M0 Stage IB | |||||||
| 21 | PK | PD | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 22 | PK | DP, PH | IDC, HCC | T3N0M0 Stage IIA/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 23 | PK | DP | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 24 | PK | PD | IDC | T3N1M0 Stage IIB/ | − | ||
| T3N1M0 Stage IIB | |||||||
| 25 | PK | DP | IDC | T3N0M0 Stage IIA/ | + | − | − |
| T3N1M0 Stage IIB | |||||||
| 26 | PK | DP | IDC | T3N0M0 Stage IIA/ | + | − | − |
| T3N0M0 Stage IIA | |||||||
| 27 | PK | PD | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N0M0 Stage IIA | |||||||
| 28 | PK | PD | IDC | T3N0M0 Stage IIA/ | + | − | − |
| T3N0M0 Stage IIA | |||||||
| 29 | PK | UR | T3N0M0 Stage IIA/ | + | + | Pm | |
| T3N0M1 Stage IV | |||||||
| 30 | PK | DP | CP | T3N0M0 Stage IIA/− | − | ||
| 31 | PK | DP | IDC | T3N0M0 Stage IIA/ | − | ||
| T3N0M0 Stage IIA/ | |||||||
| 32 | PK | SL | T4N0M0 Stage III/ | − | |||
| T4N0M0 Stage III | |||||||
| 33 | IPMC | DP | IPMC (invasive) | T3N0M0 Stage IIA/ | + | − | − |
| T3N1M0 Stage IIB | |||||||
| 34 | PK | UR | T3N0M0 Stage IIA/ | + | + | Pm | |
| T3N0M1 Stage IV | |||||||
a
UICC 6th TNM classification. UICC, Union for International Cancer Control; TNM, tumour, node and metastasis; WL, white light; BL, fluorescence light; PK, pancreatic cancer; SL, staging laparoscopy; PD, pancreaticoduodenectomy; DP, distal pancreatectomy; PH, partial hepatectomy; UR, unresectable; Pm, peritoneal metastasis; Lm, liver metastasis; CP, chronic pancreatitis; IDC, invasive ductal carcinoma; IPMC, intraductal papillary-mucinous carcinoma; in situ, adenocarcinoma in situ; HCC, hepatocellular carcinoma.